Search details
1.
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.
J Infect Dis
; 226(3): 510-520, 2022 08 26.
Article
in English
| MEDLINE | ID: mdl-35134995
2.
Social networks, mobility, and HIV risk among women in the fishing communities of Lake Victoria.
BMC Womens Health
; 22(1): 555, 2022 12 28.
Article
in English
| MEDLINE | ID: mdl-36578062
3.
Comparison of retention in observational cohorts and nested simulated HIV vaccine efficacy trials in the key populations in Uganda.
BMC Med Res Methodol
; 20(1): 32, 2020 02 12.
Article
in English
| MEDLINE | ID: mdl-32050900
4.
Comparison of HIV Risk Behaviors Between Clinical Trials and Observational Cohorts in Uganda.
AIDS Behav
; 24(10): 2872-2884, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-32277309
5.
Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection.
J Infect Dis
; 220(3): 432-441, 2019 07 02.
Article
in English
| MEDLINE | ID: mdl-30938435
6.
A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.
J Infect Dis
; 214(9): 1341-1348, 2016 Nov 01.
Article
in English
| MEDLINE | ID: mdl-27521362
7.
Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study.
medRxiv
; 2023 Nov 07.
Article
in English
| MEDLINE | ID: mdl-37986879
8.
Region-specific laboratory reference intervals are important: A systematic review of the data from Africa.
PLOS Glob Public Health
; 2(11): e0000783, 2022.
Article
in English
| MEDLINE | ID: mdl-36962599
9.
Use of propensity score matching to create counterfactual group to assess potential HIV prevention interventions.
Sci Rep
; 11(1): 7017, 2021 03 29.
Article
in English
| MEDLINE | ID: mdl-33782485
10.
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
J Virol
; 83(14): 7337-48, 2009 Jul.
Article
in English
| MEDLINE | ID: mdl-19439467
11.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Vaccine
; 38(49): 7708-7715, 2020 11 17.
Article
in English
| MEDLINE | ID: mdl-32907759
12.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Vaccine
; 38(34): 5556-5561, 2020 07 22.
Article
in English
| MEDLINE | ID: mdl-32571717
13.
Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial.
PLoS One
; 15(5): e0233151, 2020.
Article
in English
| MEDLINE | ID: mdl-32469893
14.
HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use.
Lancet HIV
; 7(2): e141-e148, 2020 02.
Article
in English
| MEDLINE | ID: mdl-31786175
15.
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
Vaccine
; 38(49): 7702-7707, 2020 11 17.
Article
in English
| MEDLINE | ID: mdl-33070999
16.
Specificity of CD8+ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya.
Vaccines (Basel)
; 8(2)2020 May 29.
Article
in English
| MEDLINE | ID: mdl-32485938
17.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Vaccine
; 38(35): 5734-5739, 2020 07 31.
Article
in English
| MEDLINE | ID: mdl-32653276
18.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Vaccine
; 38(39): 6184-6189, 2020 09 03.
Article
in English
| MEDLINE | ID: mdl-32747214
19.
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.
BMJ Open
; 10(11): e042247, 2020 11 26.
Article
in English
| MEDLINE | ID: mdl-33243815
20.
WHO's new guidelines for antiretroviral treatment.
Lancet
; 382(9907): 1778-9, 2013 Nov 30.
Article
in English
| MEDLINE | ID: mdl-24290585